LONDON and PHILADELPHIA, Nov. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline
(GSK) announces that it will create a seventh Center of Excellence for Drug
Discovery (CEDD), extending the company's new model for pharmaceutical
research and development.
The additional CEDD will concentrate on biopharmaceuticals, a field where
GSK is progressing a growing number of assets in its early-stage pipeline. The
Biopharmaceuticals CEDD will begin operations by year-end.
"The CEDDs that were created at the formation of GSK have enabled sharp
productivity gains," said Dr. Tadataka Yamada, chairman, Research and
Development, GSK. "We will now bring the well-defined accountability and
entrepreneurial drive that characterize our CEDDs to the promise of our
biopharmaceutical portfolio. We intend to become an industry leader in
providing physicians and their patients with novel biopharmaceutical
Large pharmaceutical companies traditionally specialize in medicines that
are small molecules, administered orally. Biopharmaceuticals, by contrast, are
large molecules typically administered by injection or infusion, though
research continues in other delivery technologies. Examples of
biopharmaceuticals are monoclonal antibodies, therapeutic vaccines, and
recombinant therapeutic proteins.
Currently, GSK R&D comprises six CEDDs to manage the progression of
compounds in the "middle" of the pipeline. While drawing from the broader
resources of the organization, the CEDDs bridge the conventional gap between
discovery and development. They bring together scientists and physicians who
concentrate on specific disease groupings, as follows: cardiovascular and
urogenital diseases; metabolic and viral diseases; microbial, musculoskeletal,
and proliferative diseases (cancer); neurological and gastrointestinal
diseases; psychiatric diseases; and respiratory and inflammatory diseases.
GlaxoSmithKline (NYSE: GSK), one of the world's leading research-based
pharmaceutical and healthcare companies, is committed to improving the quality
of human life by enabling people to do more, feel better and live longer. For
more information, please visit the company's web site at www.gsk.com .